Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
See Latest ArticlesTreatment of ankylosing spondylitis and other spondyloarthritides
Current Opinion in Rheumatology, 06/05/09
Braun J et al. – Review highlights the new clinical studies, efficacy regarding signs and symptoms, function and quality of life, structural damage and the link between inflammation and new bone formation. The pharmacokinetics of infliximab including the formation of antibodies and the overall and long-term safety of anti-TNF agents is also discussed.
Methods- The purpose of this review was to collect all available information related to the treatment of ankylosing spondylitis (AS) published in the year 2008
- This was achieved by a systematic literature search in PubMed
- There is increasing knowledge about the short-term and long-term efficacy of anti-TNF agents
- As of now, radiographic progression of AS pts is not decelerated, in contrast to PsA
- One major difference between the two SpAs is that AS is more an osteoproliferative disease, whereas PsA is more osteodestructive
- Methotrexate offers no additional benefit for the axial symptoms in AS
- Other biologics such as efalizumab, which is used to treat psoriasis, seems to increase the frequency of arthritis
- A whole array of potential side effects has been reported
- Cardiovascular comorbidity seems to be rather important for SpA pts
Related Articles
Evaluation of inflammation and oxidative stress in ankylosing spondylitis: a role for macrophage migration inhibitory factor
Modern Rheumatology, 10/05/09
Relevance Score: 89%
Erythrocyte sedimentation rate, CRP level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis
Arthritis Care and Research, 11/02/09
Relevance Score: 87%
Recent studies on the genetic basis of ankylosing spondylitis
Current Rheumatology Reports, 10/09/09
Relevance Score: 87%
Use of a Percutaneous Diskectomy Device to Facilitate the Diagnosis of Infectious Spondylitis
American Journal of Neuroradiology, 11/13/09
Relevance Score: 85%
A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis
Rheumatology International, 10/27/09
Relevance Score: 85%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Taking the stress out of managing gout
Canadian Family Physician, 12/16/09
Rituximab and concomitant leflunomide for the treatment of rheumatoid arthritis
Rheumatology International, 12/16/09
First-line DMARD choice in early rheumatoid arthritis - Do prognostic factors play a role?
Rheumatology, 12/15/09
Today in Spondylarthropathies...keeping you current
Receive free subspecialty "5-minute updates" via email
Programmed cell death 1 gene polymorphisms is associated with ankylosing spondylitis in Chinese Han population
Rheumatology International, 12/16/09
Human leukocyte antigen-G in ankylosing spondylitis and the response after tumour necrosis factor-&alpha blocker therapy
Rheumatology, 12/15/09
Fetuin-A and interleukin-18 levels in ankylosing spondylitis
International Journal of Rheumatic Diseases, 12/15/09
Sponsor
Article Search
Sponsor
Sponsor